葛兰素史克(GlaxoSmithKline，简称GSK)与谷歌(Google)持股公司Alphabet合作，将通过影响神经电信号的微型植入设备治疗疾病，力求在生物电子领域缔造一股强大的新生力量。
GlaxoSmithKline has teamed up with Alphabet, Google’s holding company, to treat disease through miniature implants that affect electrical signalling along nerves, with the aim of creating a powerful new force in bioelectronics.
GSK与Alphabet旗下的Verily Life Sciences（前身为谷歌生命科学(Google Life Sciences)）将联手创建Galvani Bioelectronics，开发生物电子医疗手段并将其商业化。两家公司计划在7年时间里向这家合资公司投资5.40亿英镑，并贡献现有的知识产权。
GSK and Alphabet’s Verily Life Sciences — formerly Google Life Sciences — are setting up Galvani Bioelectronics to develop and commercialise bioelectronic medicines. They plan to invest ￡540m over seven years in the jointly owned company, as well as contributing existing intellectual property.
新公司总部将设在英国，GSK将持有该公司55%股权，Verily将持有其余45%股权。Galvani的总部将设在GSK位于英国斯蒂夫尼奇(Stevenage)的主要研究中心。
GSK will own 55 per cent of the new UK-based business and Verily the remaining 45 per cent. Galvani will be based at GSK’s main UK research centre in Stevenage.
生物电子是一个新的医疗领域，致力于通过电脑化的微型植入设备治疗多种慢性病，例如关节炎、糖尿病和哮喘。这种方法可能代表着第三种治疗疾病的方法，其他两种方法是传统药物以及通过化学和生物技术开发的疫苗。
Bioelectronics is a new medical field that aims to tackle a wide range of chronic diseases, such as arthritis, diabetes and asthma, with tiny computerised implants. This approach could represent a third way of treating disease, alongside conventional medicines and vaccines developed through chemistry and biology.
自2012年GSK开始涉足生物电子领域以来一直领导GSK生物电子研究的蒙塞夫•斯拉维(Moncef Slaoui)表示：“人体很多过程由在神经系统和身体器官之间发射的电子信号控制，这些信号可能会因多种慢性病而失真。”
Moncef Slaoui, who has championed GSK’s bioelectronics research since the company started working in the field in 2012, said: “Many of the processes of the human body are controlled by electrical signals firing between the nervous system and the body’s organs, which may become distorted in many chronic diseases.